--- title: "XORTX Therapeutics (XRTX) news: going concern and offering" url: "https://aibio.space/companies/xortx-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "XRTX going concern, offering and Nasdaq notice news: XORTX reports $994,045 in cash and a going-concern note for first half of 2026. XORTX Therapeutics Inc." --- XRTX XORTX Therapeutics Inc. NASDAQ · Canada # XORTX Therapeutics (XRTX) news XRTX going concern, offering and Nasdaq notice news Listings · 2026-09-04 ## [XORTX Therapeutics files $2,500,000 paid promotion agreement with IR Agency](https://aibio.space/news/xortx-therapeutics-files-2-500-000-paid-promotion-agreement-ir-agency/) The consulting agreement covers up to 10 news releases over 3 months starting 9/3/2026. The fee is non-refundable, and the agreement says the services are promotional. ## Latest XORTX Therapeutics news 1. 2026-08-17 Listings [XORTX reports $994,045 in cash and a going-concern note for first half of 2026](https://aibio.space/news/xortx-reports-994-045-cash-going-concern-note-first-half-2026/) XORTX ended June 30, 2026 with $994,045 in cash after a $5,000,000 public offering, and the going-concern note stays. Operations used $3,768,993 in the six months. 2. 2026-02-27 Distress [XORTX auditor flags going-concern doubt in 2025 financials; cash was $864,514](https://aibio.space/news/xortx-auditor-flags-going-concern-doubt-2025-financials-cash-was-864/) The audit report says XORTX must finance its research or postpone it. The statements show an accumulated deficit of $23,824,557 at December 31, 2025. 3. 2025-05-01 Distress [XORTX Therapeutics files late-filing notice for 2024 annual report](https://aibio.space/news/xortx-therapeutics-files-late-filing-notice-2024-annual-report/) The company says it needs more time for financial reporting, closing procedures and other disclosure items. ## XORTX Therapeutics at a glance - **Ticker**: XRTX - **Listing**: NASDAQ - **Country**: Canada - **Cash, Dec 31, 2021**: C$18.9 million ### Related companies - [Devonian Health Group](https://aibio.space/companies/devonian-health/) TSXV: GSD - [BetterLife Pharma](https://aibio.space/companies/betterlife-pharma/) CSE: BETR - [Revive Therapeutics](https://aibio.space/companies/revive-therapeutics/) CSE: RVV - [EGF Theramed Health](https://aibio.space/companies/egf-theramed-health/) CSE: TMED.X - [NORTH BUD FARMS INC](https://aibio.space/companies/north-bud-farms/) OTC: NOBDF - [LUCY SCIENTIFIC DISCOVERY INC](https://aibio.space/companies/lucy-scientific-discovery/) OTC: LSDIF - [ABATTIS BIOCEUTICALS CORP](https://aibio.space/companies/abattis-bioceuticals/) OTC: ATTBF - [Defence Therapeutics](https://aibio.space/companies/defence-therapeutics/) CSE: DTC ### Also on NASDAQ - [SIGA Technologies](https://aibio.space/companies/siga-technologies/) SIGA - [ClearPoint Neuro](https://aibio.space/companies/clearpoint-neuro/) CLPT - [Maze Therapeutics](https://aibio.space/companies/maze-therapeutics/) MAZE - [CG Oncology](https://aibio.space/companies/cg-oncology/) CGON - [Kalaris Therapeutics](https://aibio.space/companies/kalaris-therapeutics/) KLRS - [Vivani Medical](https://aibio.space/companies/vivani-medical/) VANI ## What XORTX Therapeutics does XORTX Therapeutics Inc. was incorporated in British Columbia as APAC Resources Inc. and became XORTX Therapeutics through a reverse take-over of XORTX Pharma Corp. on January 10, 2018. XORTX Pharma remains its only subsidiary. Its earlier programs centred on XORLO, a proprietary oral formulation of oxypurinol, for autosomal dominant polycystic kidney disease (ADPKD). The three-year history in the filing describes a bridging pharmacokinetics trial of XORLO, an FDA orphan drug designation for oxypurinol in ADPKD, and an orphan drug designation request for the XRx-008 program. In February 2026 the company agreed to extend the time to complete its Vectus Acquisition, which the filing says was needed to transfer intellectual property. The risk factors describe an acquisition of Psyga Bio as a transformative change to the business, with product candidates that are psychedelic and nature-derived compounds in early stages of development and not approved by any regulatory authority. The company also says it is negotiating a significant financing that would require changes to its board of directors. The filing lists operations in Calgary, Alberta and a registered office in Vancouver, British Columbia. | Product or program | What it is | Stage | |---|---|---| | XORLO (oxypurinol formulation) | Proprietary oral oxypurinol formulation for ADPKD | orphan drug designation granted for oxypurinol in ADPKD | | XRx-008 program | Program for autosomal dominant polycystic kidney disease | orphan drug designation request submitted | | Psyga Bio product candidates | Psychedelic and nature-derived compounds acquired through Psyga Bio | early stages of development; not approved by any regulatory authority | Summarised from the company's [20-F filed Mar 20, 2026](https://www.sec.gov/Archives/edgar/data/1729214/000110465926032775/tmb-20251231x20f.htm). ## XORTX Therapeutics annual financials | Line | FY2021 | FY2020 | |---|---|---| | Research and development | [C$853,124](https://www.sec.gov/Archives/edgar/data/1729214/000175392622000646/) | [C$277,455](https://www.sec.gov/Archives/edgar/data/1729214/000175392622000646/) | | Net income (loss) | [-C$1.7 million](https://www.sec.gov/Archives/edgar/data/1729214/000175392622000646/) | [-C$1.3 million](https://www.sec.gov/Archives/edgar/data/1729214/000175392622000646/) | | Cash from operations | [-C$6.1 million](https://www.sec.gov/Archives/edgar/data/1729214/000175392622000646/) | [-C$728,401](https://www.sec.gov/Archives/edgar/data/1729214/000175392622000646/) | | Cash and equivalents | [C$18.9 million](https://www.sec.gov/Archives/edgar/data/1729214/000175392622000646/) | [C$171,271](https://www.sec.gov/Archives/edgar/data/1729214/000175392622000646/) | Latest balance sheet, Dec 31, 2021 (20-F): cash and equivalents C$18.9 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about XORTX Therapeutics Has XORTX Therapeutics issued a going-concern warning? Our latest story on this, dated Aug 17, 2026: "XORTX reports $994,045 in cash and a going-concern note for first half of 2026". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/xortx-reports-994-045-cash-going-concern-note-first-half-2026/). Has XORTX Therapeutics raised money recently? Our latest story on this, dated Aug 17, 2026: "XORTX reports $994,045 in cash and a going-concern note for first half of 2026". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/xortx-reports-994-045-cash-going-concern-note-first-half-2026/). Has XORTX Therapeutics received a Nasdaq deficiency notice? Our latest story on this, dated May 1, 2025: "XORTX Therapeutics files late-filing notice for 2024 annual report". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/xortx-therapeutics-files-late-filing-notice-2024-annual-report/). What is the ticker symbol of XORTX Therapeutics? XORTX Therapeutics Inc. trades under the ticker XRTX on NASDAQ. Where is XORTX Therapeutics listed? XORTX Therapeutics Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:A427MJ; LS:A427MJ; LSX:A427MJ. What is the SEC CIK of XORTX Therapeutics? The SEC Central Index Key (CIK) for XORTX Therapeutics Inc. is 1729214. Its filings are on SEC EDGAR. How many shares does XORTX Therapeutics have outstanding? 12,989,678 shares as of 2021-12-31, per the cover page of its 20-F filed 2022-05-03. Which country or territory is XORTX Therapeutics listed under? Our directory records XORTX Therapeutics Inc. under Canada. What does XORTX Therapeutics do? Our directory classifies XORTX Therapeutics Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of XORTX Therapeutics? The ISIN recorded for XORTX Therapeutics Inc. is CA98420Q4051. Does aibio.space cover XORTX Therapeutics? aibio.space lists XORTX Therapeutics Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is XORTX Therapeutics incorporated? SEC records list its state or country of incorporation as A1. What does XORTX Therapeutics develop? XORTX Therapeutics Inc. was incorporated in British Columbia as APAC Resources Inc. and became XORTX Therapeutics through a reverse take-over of XORTX Pharma Corp. on January 10, 2018. XORTX Pharma remains its only subsidiary. What is XORLO (oxypurinol formulation) from XORTX Therapeutics? XORLO (oxypurinol formulation): Proprietary oral oxypurinol formulation for ADPKD Stage: orphan drug designation granted for oxypurinol in ADPKD. What is XRx-008 program from XORTX Therapeutics? XRx-008 program: Program for autosomal dominant polycystic kidney disease Stage: orphan drug designation request submitted. ## Investor discussion: XORTX Therapeutics Members talk about XORTX Therapeutics (XRTX). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at XORTX Therapeutics, newest first. Each line links the filing it comes from. 1. 2026-09-04 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1729214/000118518526003845/xortxex99-1.htm) 2. 2026-08-28 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1729214/000117184326005782/exh_991.htm) 3. 2026-08-17 Listings Reported a reverse stock split. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1729214/000117184326005562/exh_991.htm) 4. 2026-06-12 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1729214/000117184326004098/exh_991.htm) 5. 2026-05-19 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1729214/000117184326003516/exh_991.htm) 6. 2026-05-14 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1729214/000117184326003401/exh_991.htm) 7. 2026-04-21 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1729214/000117184326002595/exh_991.htm) 8. 2026-04-01 Listings Reported a reverse stock split. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1729214/000117184326002162/exh_991.htm) 9. 2026-03-27 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1729214/000117184326001954/exh_991.htm) 10. 2026-03-24 Listings Reported a reverse stock split. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1729214/000117184326001877/exh_991.htm) 11. 2026-03-13 Listings Reported a reverse stock split. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1729214/000117184326001554/exh_991.htm) 12. 2026-02-27 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1729214/000117184326001172/exh_991.htm) 13. 2026-01-02 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1729214/000117184326000010/exh_991.htm) 14. 2025-11-17 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1729214/000117184325007387/exh_991.htm) 15. 2025-10-21 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1729214/000117184325006532/exh_991.htm) 16. 2025-09-25 Financings Filed a registration statement for a share offering. SEC Form F-1. [Source](https://www.sec.gov/Archives/edgar/data/1729214/000110465925093362/tm2522032-8_f1.htm) 17. 2025-08-15 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1729214/000117184325005439/exh_991.htm) 18. 2025-05-16 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1729214/000117184325003273/exh_991.htm) 19. 2025-05-12 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 20-F. [Source](https://www.sec.gov/Archives/edgar/data/1729214/000141057825001183/tmb-20241231x20f.htm) 20. 2025-05-01 Distress Told the SEC a periodic report would be filed late. SEC Form NT 20-F. [Source](https://www.sec.gov/Archives/edgar/data/1729214/000110465925043006/tm251325d2_nt20f.htm) 21. 2025-04-18 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1729214/000117184325002308/exh_991.htm) 22. 2025-03-26 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1729214/000117184325001717/exh_991.htm) 23. 2024-11-15 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1729214/000117184324006401/exh_991.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:XRTX on TradingView](https://www.tradingview.com/symbols/NASDAQ-XRTX/). ## SEC filings and registration - **SEC name**: XORTX Therapeutics Inc. - **CIK**: 1729214 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: XRTX (Nasdaq) - **State or country of incorporation**: A1 - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Emerging growth company - **Business address**: SUITE 2400 - 745 THURLOW STREET, VANCOUVER, British Columbia, Canada, V6E 0C5 - **Phone**: 403-607-2621 - **Shares outstanding**: 12,989,678 as of 2021-12-31 (20-F filed 2022-05-03) ### Recent filings (8-K and 6-K are the company's own announcements) - [6-K](https://www.sec.gov/Archives/edgar/data/1729214/000117184326006540/f6k_100826.htm) filed 2026-10-08 - [6-K](https://www.sec.gov/Archives/edgar/data/1729214/000117184326006109/f6k_091826.htm) filed 2026-09-18 - [6-K](https://www.sec.gov/Archives/edgar/data/1729214/000117184326005981/f6k_091026.htm) filed 2026-09-10 - [6-K](https://www.sec.gov/Archives/edgar/data/1729214/000118518526003895/xortx6k090926.htm) filed 2026-09-09 - [6-K](https://www.sec.gov/Archives/edgar/data/1729214/000118518526003845/xortx6k090226.htm) filed 2026-09-04 - [6-K](https://www.sec.gov/Archives/edgar/data/1729214/000117184326005782/f6k_082826.htm) filed 2026-08-28 - [6-K](https://www.sec.gov/Archives/edgar/data/1729214/000117184326005562/f6k_081526.htm) filed 2026-08-17 - [6-K](https://www.sec.gov/Archives/edgar/data/1729214/000117184326005158/f6k_080426.htm) filed 2026-08-04 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001729214), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details XORTX Therapeutics Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker XRTX, recorded under Canada. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: XORTX Therapeutics Inc. - **Ticker**: XRTX - **Listing**: NASDAQ - **Country or territory**: Canada - **Business scope**: Pharmaceuticals: Major - **ISIN**: CA98420Q4051 - **Other listed symbols**: GETTEX:A427MJ; LS:A427MJ; LSX:A427MJ - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-XRTX/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/xortx-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "XORTX Therapeutics (XRTX) news: going concern and offering", 2026-10-31, https://aibio.space/companies/xortx-therapeutics/